Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study-0

Fibrin/PLGA showed a significant higher (< 0.05) cells proliferation than PLGA at day-3 (*). Cells proliferation activity had declined by day-21.<p><b>Copyright information:</b></p><p>Taken from "Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study"</p><p>http://www.josr-online.com/content/3/1/17</p><p>Journal of Orthopaedic Surgery and Research 2008;3():17-17.</p><p>Published online 25 Apr 2008</p><p>PMCID:PMC2405772.</p><p></p

Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study-1

And PLGA construct (Figure 2C) was morphologically similar after 7 days in culture. Fibrin/PLGA construct (Figure 2D) showed slightly smooth and glistening morphology when compared to PLGA (Figure 2E) after 14 days. By week 3, fibrin/PLGA construct appeared whiter, smoother and glistening (Figure 2F) than PLGA (Figure 2G).<p><b>Copyright information:</b></p><p>Taken from "Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study"</p><p>http://www.josr-online.com/content/3/1/17</p><p>Journal of Orthopaedic Surgery and Research 2008;3():17-17.</p><p>Published online 25 Apr 2008</p><p>PMCID:PMC2405772.</p><p></p

Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study-4

Ressed in fibrin/PLGA and PLGA. Interestingly, suppression of collagen type I was observed in fibrin/PLGA and PLGA at 2 weeks and 3 weeks. β-actin gene was steadily expressed in all samples to verify the analysis was reliable and successful.<p><b>Copyright information:</b></p><p>Taken from "Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study"</p><p>http://www.josr-online.com/content/3/1/17</p><p>Journal of Orthopaedic Surgery and Research 2008;3():17-17.</p><p>Published online 25 Apr 2008</p><p>PMCID:PMC2405772.</p><p></p

Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study-5

respectively. After 2 and 3 weeks , PLGA demonstrated significantly higher wet weight (< 0.05) compared to fibrin/PLGA. The sGAG production in fibrin/PLGA construct was superior to PLGA. Relative sGAG contents (%) were significantly higher (< 0.05) in fibrin/PLGA than PLGA at 1 week and 3 weeks.<p><b>Copyright information:</b></p><p>Taken from "Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study"</p><p>http://www.josr-online.com/content/3/1/17</p><p>Journal of Orthopaedic Surgery and Research 2008;3():17-17.</p><p>Published online 25 Apr 2008</p><p>PMCID:PMC2405772.</p><p></p

Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study-3

Cellular and inter-territorial matrix. Minimal collagen type II expression could be observed in the PLGA construct (Figure 4C). After 3 weeks, collagen type II expression was maintained in fibrin/PLGA (Figure 4E) and PLGA (Figure G). Collagen type I in fibrin/PLGA constructs showed moderate immunopositivity at week-2 (Figure 4B) and week-3 (Figure 4F), as did PLGA (Figure 4D, Figure 4H).<p><b>Copyright information:</b></p><p>Taken from "Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study"</p><p>http://www.josr-online.com/content/3/1/17</p><p>Journal of Orthopaedic Surgery and Research 2008;3():17-17.</p><p>Published online 25 Apr 2008</p><p>PMCID:PMC2405772.</p><p></p

Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study-2

fibrin/PLGA (Figure 3A, B, C and Figure 3G, H, I) and PLGA (Figure 3D, E, F and Figure 3J, K, L) were clearly visible in term of overall cartilaginous tissue formation, cells organization and ECM distribution. The fibrin/PLGA constructs was intensely stained with Safranin O for accumulated proteoglycan and Alcian Blue for GAG at 2 weeks and greatest at 3 weeks.<p><b>Copyright information:</b></p><p>Taken from "Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study"</p><p>http://www.josr-online.com/content/3/1/17</p><p>Journal of Orthopaedic Surgery and Research 2008;3():17-17.</p><p>Published online 25 Apr 2008</p><p>PMCID:PMC2405772.</p><p></p

Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study-6

Fibrin/PLGA showed a significant higher (< 0.05) cells proliferation than PLGA at day-3 (*). Cells proliferation activity had declined by day-21.<p><b>Copyright information:</b></p><p>Taken from "Fibrin and poly(lactic-co-glycolic acid) hybrid scaffold promotes early chondrogenesis of articular chondrocytes: an study"</p><p>http://www.josr-online.com/content/3/1/17</p><p>Journal of Orthopaedic Surgery and Research 2008;3():17-17.</p><p>Published online 25 Apr 2008</p><p>PMCID:PMC2405772.</p><p></p

Bioengineered Osteoinductive <i>Broussonetia kazinoki</i>/Silk Fibroin Composite Scaffolds for Bone Tissue Regeneration

In this article, <i>Broussonetia kazinoki</i> (BK) powdery extract is utilized to modify the silk fibroin (SF) scaffold and applied to the bone defect area. The BK/SF scaffold is an efficient cell carrier which promotes cell proliferation and osteogenic differentiation of rBMSCs (bone marrow derived mesenchymal stem cells). We confirmed biocompatibility and osteogenic differentiation capacity of BK/SF scaffolds compared to pristine SF scaffold in both <i>in vitro</i> and <i>in vivo</i> evaluation. Gene expression related to osteogenic differentiation and bone regeneration significantly upregulated in the BK/SF scaffold group. The implanted scaffolds were attached well to the surface of the bone defect region and integrated with surrounding tissues without significant inflammatory reaction. Furthermore, almost 45% of bone volume has been recovered at 8 weeks postsurgery, while the SF and control group showed 20% recovery. These results suggest that BK powdery extract incorporated with an SF scaffold might be a suitable substitute for an alternative bone graft for bone regeneration

Dual Stimuli-Activatable Oxidative Stress Amplifying Agent as a Hybrid Anticancer Prodrug

Compared to normal cells, cancer cells have a higher level of reactive oxygen species (ROS) due to aberrant metabolism and disruption of redox homeostasis which drive their proliferation and promote progression and metastasis of cancers. The altered redox balance and biological difference between normal cells and cancer cells provide a basis for the development of anticancer agents which are able to generate pharmacological ROS insults to kill cancer cells preferentially. In this study, we report a new hybrid anticancer drug, termed OSamp, which undergoes esterase- and acid-catalyzed hydrolysis to deplete antioxidant glutathione (GSH) and generate ROS, simultaneously. OSamp significantly elevated oxidative stress in cancer cells, leading to enhanced apoptotic cancer cell death through mitochondrial membrane disruption, cytochrome c release, activation of pro-caspase 3, and deactivation of STAT3 (signal transducer and activator of transcription-3). OSamp, administered intravenously, significantly suppressed the tumor growth in a mouse model of tumor xenografts without notable side effects. Oxidative stress amplifying OSamp holds tremendous potential as a new anticancer therapeutic and provides a new therapeutic paradigm which can be extended to development of hybrid anticancer drugs